Physician profile
Amer Skopic
NPI 1811099104
$15,222.39
in general payments reported to CMS, 2019-2025
23 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $1,854 · 2021: $647 · 2022: $805 · 2023: $1,014 · 2024: $8,852 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,310 · Food and Beverage: $3,552 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,310.00 |
| Food and Beverage | $3,552.29 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $7,860.66 | 2023-2025 | Voquezna |
| Abbvie INC. | $1,699.12 | 2019-2025 | Skyrizi, Viberzi, Linzess |
| Allergan, INC. | $1,572.89 | 2019-2020 | |
| Janssen Biotech, INC. | $1,095.50 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $620.10 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $451.59 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.37 | 2019-2023 | Xifaxan |
| Celgene Corporation | $317.86 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $255.30 | 2019-2024 | Linzess |
| Pfizer INC. | $237.56 | 2021-2025 | |
| Braintree Laboratories, INC. | $140.38 | 2023-2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $122.55 | 2022-2025 | Dupixent |
| Ethicon US, LLC | $102.40 | 2019 | |
| Ardelyx, INC. | $79.19 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $75.11 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $43.71 | 2024 | |
| Genzyme Corporation | $42.45 | 2024-2025 | |
| Novo Nordisk INC | $41.82 | 2025 | Wegovy |
| Ucb, INC. | $32.31 | 2019 | |
| Boston Scientific Corporation | $22.54 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.61 | 2023 | Cyltezo |
| Shire North American Group INC | $16.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Skopic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.